Iridex (IRIX) Short term Debt (2020 - 2021)

Iridex (IRIX) posted quarterly Short term Debt of $2.2 million for Q2 2021, up 74.94% quarter-over-quarter from $1.2 million in Q1 2021.

Iridex (IRIX) Short term Debt (2020 - 2021) Analysis & Trends

Iridex's Short term Debt history runs 2 years deep, the most recent figure standing at $2.2 million for Q2 2021.

In Q2 2021, Short term Debt changed N/A year-over-year to $2.2 million; the TTM figure through Apr 2021 stood at $2.2 million (changed N/A YoY), while the FY2021 annual figure was $1.2 million, changed N/A from the prior year.
Short term Debt for Q2 2021 stood at $2.2 million, up from $1.2 million in the prior quarter.
The five-year high for Short term Debt was $2.2 million in Q2 2021, with the low at $1.2 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Iridex	13.27 Mn	8.59 Mn	4.30 Mn

Download Data